• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

晚期糖基化终产物在雌激素受体阳性乳腺癌患者中升高,改变对治疗的反应,并且可以通过生活方式干预来靶向。

Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention.

机构信息

Department of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA.

Department of Public Health Sciences, MUSC, Charleston, SC, USA.

出版信息

Breast Cancer Res Treat. 2019 Feb;173(3):559-571. doi: 10.1007/s10549-018-4992-7. Epub 2018 Oct 27.

DOI:10.1007/s10549-018-4992-7
PMID:30368741
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6394600/
Abstract

PURPOSE

Lifestyle factors associated with personal behavior can alter tumor-associated biological pathways and thereby increase cancer risk, growth, and disease recurrence. Advanced glycation end products (AGEs) are reactive metabolites produced endogenously as a by-product of normal metabolism. A Western lifestyle also promotes AGE accumulation in the body which is associated with disease phenotypes through modification of the genome, protein crosslinking/dysfunction, and aberrant cell signaling. Given the links between lifestyle, AGEs, and disease, we examined the association between dietary-AGEs and breast cancer.

METHODS

We evaluated AGE levels in bio-specimens from estrogen receptor-positive (ER+) and estrogen receptor-negative (ER-) breast cancer patients, examined their role in therapy resistance, and assessed the ability of lifestyle intervention to reduce circulating AGE levels in ER+ breast cancer survivors.

RESULTS

An association between ER status and AGE levels was observed in tumor and serum samples. AGE treatment of ER+ breast cancer cells altered ERα phosphorylation and promoted resistance to tamoxifen therapy. In a proof of concept study, physical activity and dietary intervention was shown to be viable options for reducing circulating AGE levels in breast cancer survivors.

CONCLUSIONS

There is a potential prognostic and therapeutic role for lifestyle derived AGEs in breast cancer. Given the potential benefits of lifestyle intervention on incidence and mortality, opportunities exist for the development of community health and nutritional programs aimed at reducing AGE exposure in order to improve breast cancer prevention and treatment outcomes.

摘要

目的

与个人行为相关的生活方式因素可以改变与肿瘤相关的生物学途径,从而增加癌症风险、生长和疾病复发。晚期糖基化终产物(AGEs)是内源性产生的反应性代谢物,是正常代谢的副产物。西方生活方式也促进了体内 AGE 的积累,通过修饰基因组、蛋白质交联/功能障碍和异常细胞信号转导,与疾病表型相关。鉴于生活方式、AGEs 和疾病之间的联系,我们研究了饮食-AGEs 与乳腺癌之间的关联。

方法

我们评估了雌激素受体阳性(ER+)和雌激素受体阴性(ER-)乳腺癌患者生物样本中的 AGE 水平,研究了它们在治疗耐药性中的作用,并评估了生活方式干预降低 ER+乳腺癌幸存者循环 AGE 水平的能力。

结果

在肿瘤和血清样本中观察到 ER 状态与 AGE 水平之间存在关联。AGE 处理 ER+乳腺癌细胞改变了 ERα 磷酸化并促进了对他莫昔芬治疗的耐药性。在一项概念验证研究中,运动和饮食干预被证明是降低乳腺癌幸存者循环 AGE 水平的可行选择。

结论

生活方式衍生的 AGEs 在乳腺癌中具有潜在的预后和治疗作用。鉴于生活方式干预对发病率和死亡率的潜在益处,存在开发社区健康和营养计划的机会,以减少 AGE 暴露,从而改善乳腺癌的预防和治疗结果。

相似文献

1
Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention.晚期糖基化终产物在雌激素受体阳性乳腺癌患者中升高,改变对治疗的反应,并且可以通过生活方式干预来靶向。
Breast Cancer Res Treat. 2019 Feb;173(3):559-571. doi: 10.1007/s10549-018-4992-7. Epub 2018 Oct 27.
2
Accumulation of the advanced glycation end product carboxymethyl lysine in breast cancer is positively associated with estrogen receptor expression and unfavorable prognosis in estrogen receptor-negative cases.晚期糖基化终产物羧甲基赖氨酸在乳腺癌中的积累与雌激素受体表达呈正相关,且在雌激素受体阴性病例中与不良预后相关。
Histochem Cell Biol. 2017 May;147(5):625-634. doi: 10.1007/s00418-016-1534-4. Epub 2016 Dec 23.
3
Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients.辅助他莫昔芬导致的乳腺 X 线密度降低可预测雌激素受体阳性绝经前乳腺癌患者的复发。
Breast Cancer Res Treat. 2013 Dec;142(3):559-67. doi: 10.1007/s10549-013-2726-4.
4
Biological impact of advanced glycation endproducts on estrogen receptor-positive MCF-7 breast cancer cells.晚期糖基化终产物对雌激素受体阳性 MCF-7 乳腺癌细胞的生物学影响。
Biochim Biophys Acta Mol Basis Dis. 2017 Nov;1863(11):2808-2820. doi: 10.1016/j.bbadis.2017.07.011. Epub 2017 Jul 13.
5
Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.他莫昔芬耐药乳腺癌细胞中上皮-间质转化表型的获得:G蛋白偶联雌激素受体在通过肿瘤相关成纤维细胞衍生的纤连蛋白和肿瘤细胞中的β1整合素信号通路介导他莫昔芬耐药中的新作用。
Breast Cancer Res. 2015 May 21;17(1):69. doi: 10.1186/s13058-015-0579-y.
6
Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells.靶向一氧化氮治疗抑制雌激素受体阳性乳腺癌细胞的干性并提高他莫昔芬的疗效。
Lab Invest. 2021 Mar;101(3):292-303. doi: 10.1038/s41374-020-00507-z. Epub 2020 Dec 1.
7
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.他莫昔芬耐药机制:雌激素受体与HER2/neu在ER/HER2阳性乳腺癌中相互作用增强
J Natl Cancer Inst. 2004 Jun 16;96(12):926-35. doi: 10.1093/jnci/djh166.
8
Tamoxifen resistance: from cell culture experiments towards novel biomarkers.他莫昔芬耐药性:从细胞培养实验到新型生物标志物
Pathol Res Pract. 2015 Mar;211(3):189-97. doi: 10.1016/j.prp.2015.01.004. Epub 2015 Jan 21.
9
Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.他莫昔芬治疗晚期乳腺癌的耐药机制。
Acta Oncol. 1996;35 Suppl 5:9-14. doi: 10.3109/02841869609083961.
10
Therapeutic targeting in the estrogen receptor hormonal pathway.雌激素受体激素途径中的治疗靶点。
Semin Oncol. 2004 Feb;31(1 Suppl 3):28-38. doi: 10.1053/j.seminoncol.2004.01.004.

引用本文的文献

1
Association of Dietary Advanced Glycation End Products with Overall and Site-Specific Cancer Risk and Mortality: A Systematic Review and Meta-Analysis.膳食晚期糖基化终产物与总体及特定部位癌症风险和死亡率的关联:一项系统评价和荟萃分析
Nutrients. 2025 May 10;17(10):1638. doi: 10.3390/nu17101638.
2
RAGE and its ligands in breast cancer progression and metastasis.RAGE及其配体在乳腺癌进展和转移中的作用
Oncol Rev. 2025 Jan 3;18:1507942. doi: 10.3389/or.2024.1507942. eCollection 2024.
3
Dietary advanced glycation end-products (dAGEs) are not associated with the risk of cancer incidence. A systematic review and meta-analysis of prospective cohort studies.

本文引用的文献

1
The Role of Advanced Glycation End-Products in Cancer Disparity.晚期糖基化终产物在癌症差异中的作用。
Adv Cancer Res. 2017;133:1-22. doi: 10.1016/bs.acr.2016.08.001. Epub 2016 Oct 12.
2
Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: a randomised controlled trial.口服年龄限制改善代谢综合征肥胖个体的胰岛素抵抗:一项随机对照试验。
Diabetologia. 2016 Oct;59(10):2181-92. doi: 10.1007/s00125-016-4053-x. Epub 2016 Jul 29.
3
Advanced glycation end-products: a biological consequence of lifestyle contributing to cancer disparity.
膳食晚期糖基化终产物(dAGEs)与癌症发病风险无关。一项前瞻性队列研究的系统评价和荟萃分析。
Food Sci Nutr. 2024 Aug 11;12(10):7788-7797. doi: 10.1002/fsn3.4396. eCollection 2024 Oct.
4
The RAGE Axis: A Relevant Inflammatory Hub in Human Diseases.RAGE轴:人类疾病中一个相关的炎症枢纽。
Biomolecules. 2024 Mar 28;14(4):412. doi: 10.3390/biom14040412.
5
Nε-Carboxymethyl-Lysine Modification of Extracellular Matrix Proteins Augments Fibroblast Activation.细胞外基质蛋白的 Nε-羧甲基赖氨酸修饰增强成纤维细胞的活化。
Int J Mol Sci. 2023 Oct 31;24(21):15811. doi: 10.3390/ijms242115811.
6
Pubertal exposure to dietary advanced glycation end products disrupts ductal morphogenesis and induces atypical hyperplasia in the mammary gland.青春期摄入饮食中的晚期糖基化终产物会破坏乳腺导管形态发生,并诱导乳腺非典型增生。
Breast Cancer Res. 2023 Oct 6;25(1):118. doi: 10.1186/s13058-023-01714-4.
7
Genetically Modified Circulating Levels of Advanced Glycation End-Products and Their Soluble Receptor (AGEs-RAGE Axis) with Risk and Mortality of Breast Cancer.晚期糖基化终末产物及其可溶性受体的基因修饰循环水平(AGEs-RAGE轴)与乳腺癌的风险和死亡率
Cancers (Basel). 2022 Dec 12;14(24):6124. doi: 10.3390/cancers14246124.
8
The AGEs/RAGE Transduction Signaling Prompts IL-8/CXCR1/2-Mediated Interaction between Cancer-Associated Fibroblasts (CAFs) and Breast Cancer Cells.AGEs/RAGE 转导信号提示 IL-8/CXCR1/2 介导的癌相关成纤维细胞(CAFs)与乳腺癌细胞之间的相互作用。
Cells. 2022 Aug 4;11(15):2402. doi: 10.3390/cells11152402.
9
The role of AGEs in pathogenesis of cartilage destruction in osteoarthritis.晚期糖基化终末产物在骨关节炎软骨破坏发病机制中的作用。
Bone Joint Res. 2022 May;11(5):292-300. doi: 10.1302/2046-3758.115.BJR-2021-0334.R1.
10
History of malignant neoplasia lessens oocyte developmental competence: a case-control study.恶性肿瘤病史降低卵母细胞发育能力:一项病例对照研究。
JBRA Assist Reprod. 2023 Mar 30;27(1):9-14. doi: 10.5935/1518-0557.20210113.
晚期糖基化终产物:一种导致癌症差异的生活方式的生物学后果。
Cancer Res. 2015 May 15;75(10):1925-9. doi: 10.1158/0008-5472.CAN-15-0169. Epub 2015 Apr 28.
4
Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.比较 ER 和芳香化酶过表达小鼠乳腺前期病变中他莫昔芬和来曲唑的反应,定义与他莫昔芬耐药相关的免疫相关基因特征。
Carcinogenesis. 2015 Jan;36(1):122-32. doi: 10.1093/carcin/bgu237. Epub 2014 Nov 23.
5
AGE metabolites: a biomarker linked to cancer disparity?衰老代谢物:一种与癌症差异相关的生物标志物?
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2186-91. doi: 10.1158/1055-9965.EPI-14-0564. Epub 2014 Jul 22.
6
Role of advanced glycation end products in cellular signaling.晚期糖基化终末产物在细胞信号传导中的作用。
Redox Biol. 2014 Jan 9;2:411-29. doi: 10.1016/j.redox.2013.12.016. eCollection 2014.
7
Knockdown of receptor for advanced glycation end products attenuate 17α-ethinyl-estradiol dependent proliferation and survival of MCF-7 breast cancer cells.抑制晚期糖基化终产物受体可减弱17α-乙炔基雌二醇依赖的MCF-7乳腺癌细胞的增殖和存活。
Biochim Biophys Acta. 2014 Mar;1840(3):1083-91. doi: 10.1016/j.bbagen.2013.11.014. Epub 2013 Nov 16.
8
Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.乳腺癌内分泌治疗耐药机制:聚焦信号通路、微小RNA及基于基因的耐药性
Int J Mol Sci. 2012 Dec 20;14(1):108-45. doi: 10.3390/ijms14010108.
9
Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study.预测他莫昔芬治疗的雌激素受体阳性、高风险、原发性乳腺癌患者结局的基因表达谱:DBCG 研究。
PLoS One. 2013;8(1):e54078. doi: 10.1371/journal.pone.0054078. Epub 2013 Jan 16.
10
The interaction between ER and NFκB in resistance to endocrine therapy.雌激素受体(ER)与核因子κB(NFκB)在抗内分泌治疗中的相互作用。
Breast Cancer Res. 2012 Aug 31;14(4):212. doi: 10.1186/bcr3196.